血管紧张素调节剂与特发性肺纤维化病程的关联
该研究对CAPACITY与ASCEND试验中624例随机分配至安慰剂的特发性肺纤维化(IPF)患者进行事后分析,按基线降压治疗分组,评估52周内疾病进展与全因死亡。结果显示ACEi治疗与较慢的疾病进展相关,ARB治疗则与更高的全因死亡风险相关;上述观察在纳入INSPIRE试验患者的汇总分析中得到验证。
要点
- ARB治疗与更高的全因死亡风险相关(HR 2.5,95%CI 1.2-5.2)。
- 结果来自安慰剂组事后分析,尚需前瞻性临床试验验证。
核心结论
- ACEi治疗与较慢的IPF疾病进展相关,ARB治疗与更高的全因死亡风险相关,需前瞻性临床试验验证血管紧张素调节剂对IPF临床结局的潜在获益。
研究设计与样本
- CAPACITY和ASCEND研究中所有随机分配至安慰剂的患者(n=624),按基线降压治疗分组,评估52周结局;并在纳入INSPIRE试验患者的汇总分析中验证观察结果。
主要发现
- 基线时111例使用ACEi、121例使用ARB、392例两者均未使用。
- ARB组全因死亡风险更高(HR 2.5,95%CI 1.2-5.2)。
临床怎么用
- 对合并高血压的IPF患者,ACEi治疗可能与较慢的疾病进展相关,而ARB与更高的全因死亡风险相关,提示临床选择降压药物时需综合评估。
局限性
- 为对安慰剂组的事后分析,治疗分组非随机,可能存在残余混杂,结论需前瞻性临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiotensin peptides have been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis. Angiotensin modulators are used to treat arterial hypertension, a frequent comorbidity of IPF. This post hoc analysis evaluated associations of antihypertensive treatments with disease-related outcomes in IPF. METHODS: All patients randomized to placebo (n = 624) in the CAPACITY and ASCEND studies were categorized by antihypertensive treatment at baseline. Outcomes of disease progression (first occurrence of ≥ 10% absolute decline in % predicted FVC, ≥ 50-m decline in 6-min walk distance, or death) and all-cause mortality were assessed over 52 weeks. RESULTS: At baseline, 111 and 121 patients were receiving an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), respectively; 392 were receiving neither. In multivariable analyses adjusted for differences in baseline characteristics compared with the non-ACEi/ARB group, ACEi treatment (hazard ratio [HR], 0.6 [95% CI, 0.4-0.9]; P = .026), but not ARB (HR, 0.9 [95% CI, 0.6-1.2]; P = .413), was associated with slower disease progression. Furthermore, the increase in all-cause mortality associated with cardiovascular disease was not observed in the ACEi group (HR, 1.1 [95% CI, 0.5-2.9]; P = .782), which presented a similar percentage of IPF-related mortality as the non-ACEi/ARB group (3.6% vs 3.6%). In contrast, patients in the ARB group had greater risk of all-cause mortality (HR, 2.5 [95% CI, 1.2-5.2]). These observations were validated in a pooled analysis that included patients from the INSPIRE trial. CONCLUSIONS: Prospective clinical trials are needed to evaluate whether angiotensin modulators may be beneficial to clinical outcomes in IPF. TRIAL REGISTRY: ClinicalTrials.gov; Nos.: NCT01366209, NCT00287716, NCT00287729, NCT00075998; URL: www.clinicaltrials.gov).
引用
- Kreuter M, Lederer DJ, Molina-Molina M, et al. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. Chest. 2019. PMID: 31047956. doi:10.1016/j.chest.2019.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。